Wed, Aug 27, 2014, 5:00 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • wherestherestofthismoose wherestherestofthismoose Jul 2, 2001 10:53 AM Flag

    was the 17% MDT news..

    ever released by AVII?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It doesn't look like AVII was one of those
      corrected.

      If those trades (250k) or so stand - - they
      sure could be putting pressure on the price
      today - - almost 10% overnight!!!!!!!!! Not
      a bad days work.

      Take Care

      Chuck

    • Medtronic Has 17% AVI BioPharma Stake With Investment
      Updated: Friday, June 29, 2001 10:28 AM ET Email this article to a friend!


      WASHINGTON (Dow Jones)--Medtronic Inc. (MDT, news, msgs) has a 17% beneficial stake in AVI BioPharma Inc. (AVII, news, msgs) as a result of an equity investment Medtronic made in the developer of cancer and cardiovascular therapeutic products.

      According to an original Schedule 13D filed Friday with the Securities and Exchange Commission, Medtronic beneficially owns 4,408,451 shares of AVI BioPharma common stock.

      On June 20, Medtronic's Medtronic Asset Management Inc. unit bought 1,408,451 AVI BioPharma common shares at $7.10 a share. The subsidiary also received a warrant to buy an additional 3 million AVI BioPharma common shares at $10 a share exercisable any time during the five years after June 20.

      As reported May 22, Medtronic and AVI BioPharma signed an agreement to license a family of antisense compounds, including Resten-NG. Medtronic will load those compounds on medical devices, including stents.

      As part of the pact, Medtronic's asset management unit can buy up to $10 million in additional AVI BioPharma common shares, subject to achieving certain milestones and receiving certain governmental and regulatory approvals.

      The alliance will target restenosis, which is the renarrowing or reclogging of arteries following balloon angioplasty or placement of a stent. Resten-NG is in Phase II clinical trials.

      Medtronic, of Minneapolis, is a medical technology company that develops and makes implantable and interventional medical products for people with chronic disease.

      -By Kevin Guerrero, Dow Jones Newswires; 202-628-7667; kevin.guerrero@dowjones.com

      • 1 Reply to zzzdq
      • Maybe we had some profit taking from the secondary offering back in july of last year.


        AVI BioPharma, Inc. Raises $20 Million

        8/2/2000 6:45:00 AM
        PORTLAND, Ore., Aug 2, 2000 (BW HealthWire) -- AVI BioPharma, Inc. (AVII) , (AVIIW) , (AVIIZ) today announced the completion of a secondary public offering of 3 million shares of Common Stock at a price of $7.25 per share, with net proceeds to the Company of approximately $20 million.

 
SRPT
22.84-0.36(-1.55%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.